Fig. 8
Protection efficacy of LysSYL in a mouse peritonitis model. A Survival of mice. Mice (n = 6 for each group) were intraperitoneally infected with S. aureus USA300 (108 CFU) and treated with LysSYL (12.5, 25, or 50 mg/kg) or VAN (1.25, 2.5, or 5 mg/kg) after 1 h of infection. PBS-treated mice were used as control. Mouse survival was recorded for 7 days. The analyses were measured by simple survival analysis (Kaplan-Meier). *P < 0.05, **P < 0.01, and ***P < 0.001. B Bacterial count in the indicated mouse samples. S. aureus USA300 (108 CFU) infected mice (n = 5) were treated one time with LysSYL (50 mg/kg) or VAN (5 mg/kg), and the blood sample, liver, spleen, lungs, and kidneys were collected after 24 h of treatment and subjected to bacterial counting. PBS-treated mice used as negative control. The analyses were measured by two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ns indicated no significance relative to the PBS control. C Protection efficacy of LysSYL on organ injury. Liver, spleen, lungs, and kidneys were harvested from mice sacrificed at 3 d after infection. Unclear hepatic lobule structures, disordered hepatocytes, and hepatic sinusoidal dilation were indicated by yellow arrows. Splenic red pulp congestion and reactive enlarged splenic nodules were indicated by white arrows and green arrows, respectively. Diffuse infiltration of inflammatory cells and shrunken alveolar cavities were shown by blue arrows and red arrows, respectively. Atrophic renal tubules were indicated by black arrows. Edema and degeneration of renal tubular epithelial cells were showed by pink arrows